This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NUB1 / NEDD8 ultimate buster 1 · IHC design guide
Design Immunohistochemistry for NUB1
Plan NUB1 chromogenic IHC in paraffin sections using the catalog antibody at 2–5 μg/ml (datasheet A06089-2). Compare nuclear and cytoplasmic staining across cell types, using lung macrophages as a high-staining reference (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NUB1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear and cytoplasmic staining varies by cell type (HPA tissue IHC). | |
| Staining pattern | Variable nuclear and cytoplasmic staining in most cell types (HPA tissue IHC). | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A06089-2) | |
| Positive control | Lung+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06089-2) | |
| Caveat | Macrophage-rich areas may dominate staining (HPA tissue IHC). | |
| Regulation | Intensity varies by cell type (HPA tissue IHC). | |
| Isoform / epitope | 2 isoforms; verify epitope coverage for each (UniProt). |
Section 1
Recommended NUB1 IHC & IF Protocols
The catalog antibody protocol uses EDTA pH 8.0 retrieval (datasheet A06089-2). The published NUB1 IHC protocols below cover frozen synovium, mouse and human sections, and paraffin breast tissue (PMC12960655; PMC3181070; PMC12189139).
| Sample | Paraffin-embedded human adrenal adenomas tissue; fixative not specified (datasheet A06089-2) |
| Fixation | Image fixative and duration unreported (datasheet A06089-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A06089-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06089-2) |
| Primary antibody | Rabbit anti-NUB1, 2-5 μg/ml (datasheet A06089-2) |
| Primary incubation | Overnight at 4 °C (datasheet A06089-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A06089-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NUB1-positive staining in macrophages of lung (HPA tissue IHC: High). HPA tissue profile: Nuclear and cytoplasmic expression with variable intensity in most cell types. No signal in the no-primary control. |
💡Decision noteFor paraffin sections, start with heat-mediated EDTA pH 8.0 retrieval (datasheet A06089-2); compare published retrieval conditions when working with the corresponding samples (PMC3181070; PMC12189139).
Section 2
What Is the Expected NUB1 Staining Pattern?
NUB1 is predominantly nuclear (UniProt Q9Y5A7), while tissue IHC shows nuclear and cytoplasmic staining of variable intensity in most cell types (HPA tissue IHC). Expect strong staining in lung macrophages and moderate staining in several glandular and hematopoietic cell populations (HPA tissue IHC). HPA rates the tissue profile Approved, with medium consistency between antibody staining and RNA expression (HPA tissue IHC). NUB1 has no transmembrane segment (UniProt Q9Y5A7 topology).
| Nuclear staining, sometimes accompanied by cytoplasmic staining, in lung macrophages. | This fits the High macrophage signal and mixed nuclear–cytoplasmic tissue pattern (HPA tissue IHC). Compare compartments within identifiable macrophages; cytoplasmic staining alone is less consistent with NUB1's predominantly nuclear localisation (UniProt Q9Y5A7). |
| Moderate staining in glandular cells of colon, appendix or adrenal gland, or in bone marrow hematopoietic cells. | These are reported Medium populations (HPA tissue IHC). Judge intensity within the specified cell population rather than treating every cell in the section as an equally strong positive (HPA tissue IHC). |
| A predominantly membrane-rim or extracellular pattern, with little intracellular staining. | This conflicts with the reported nuclear and cytoplasmic tissue pattern (HPA tissue IHC) and lack of a transmembrane segment (UniProt Q9Y5A7 topology). Treat it as a possible artefact and inspect morphology and controls before assigning it to NUB1 (general IHC practice). |
| Strong staining in adipocytes or salivary gland glandular cells, populations reported as undetected. | These are useful unexpected-signal checks, though an HPA 'Not detected' call is not proof of absolute absence (HPA tissue IHC). Consider cross-reactivity or endogenous detection activity and compare a no-primary control (general IHC practice). |
| Haze across tissue and blank areas, or no staining in lung macrophages. | Diffuse colour that ignores cell boundaries suggests background; compare a no-primary control (general IHC practice). Absent macrophage signal conflicts with the reported High level (HPA tissue IHC); check the run controls and staining workflow before interpreting the specimen as negative (general IHC practice). |
💡Expected NUB1 appearanceA convincing positive shows intracellular nuclear staining, with possible cytoplasmic signal, in identifiable lung macrophages at High intensity (HPA tissue IHC; UniProt Q9Y5A7); strong membrane-only staining or colour outside cells is suspect (general IHC practice).
| Cell population and tissue context | HPA reports High lung macrophages, Medium cells in several glands and bone marrow, and variable staining across most cell types (HPA tissue IHC). Select and score the named cells, since the tissue name alone does not define the expected intensity (general IHC practice). |
| Subcellular distribution and topology | Predominantly nuclear localisation (UniProt Q9Y5A7) is compatible with HPA's nuclear and cytoplasmic tissue staining (HPA tissue IHC). NUB1 has no transmembrane segment (UniProt Q9Y5A7 topology), so a membrane-only pattern warrants review. |
| Isoforms and processing | UniProt lists 2 isoforms, no signal peptide or propeptide, and a full-length chain spanning residues 1–615 (UniProt Q9Y5A7). The supplied record gives no antibody epitope, so it cannot establish which isoform the catalog antibody detects or predict an isoform-specific IHC pattern. |
| Strength of the tissue evidence | The overall HPA tissue profile is Approved but has medium antibody–RNA consistency (HPA tissue IHC). HPA021220 and HPA050722 have Approved IHC status (HPA antibodies); that status supports using their observations as references without making every apparent positive conclusive. |
| IF/ICC Q: where should signal appear? | A: HPA reports enhanced nucleoplasm and nucleoli localisation in ICC-IF images from HEK293, MCF-7 and U2OS (HPA subcellular). HPA050722 and HPA053648 have Supported ICC status (HPA antibodies). Interpret this as an IF localisation reference; the supplied sources give no IF protocol here. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in lung macrophages on a stained paraffin section. | That result disagrees with the reported High macrophage staining (HPA tissue IHC); a failed staining run remains possible (general IHC practice). | Confirm macrophage identity and inspect the run's positive control, retrieval record, primary-antibody dilution and detection steps (general IHC practice). The supplied sources do not establish NUB1-specific retrieval or fixation sensitivity. |
| Only diffuse brown colour, including regions without identifiable cells. | A cell-independent pattern is consistent with background or endogenous detection activity (general IHC practice), rather than the cellular pattern reported by HPA (HPA tissue IHC). | Compare a no-primary control; check blocking, washes and endogenous-enzyme control appropriate to the chromogenic system (general IHC practice). Score only signal that resolves to identifiable cells. |
| A sharp membrane outline dominates, with no convincing nuclear signal. | NUB1 is predominantly nuclear (UniProt Q9Y5A7), and HPA tissue staining is nuclear and cytoplasmic (HPA tissue IHC); membrane-only signal is discordant. | Review the same cell type in a reported positive tissue and compare controls (HPA tissue IHC; general IHC practice). Do not count a membrane outline alone as the expected NUB1 pattern. |
| Strong signal appears in adipocytes or salivary gland glandular cells. | Both populations are listed as Not detected (HPA tissue IHC). Cross-reactivity or endogenous activity may explain an unexpected positive (general IHC practice). | Check a no-primary control and cell morphology, then compare with a reported positive population (general IHC practice; HPA tissue IHC). Record the discrepancy; the HPA call does not prove absolute absence. |
| Cytoplasmic signal is present but nuclear signal is weak. | Cytoplasmic tissue staining can occur (HPA tissue IHC), although NUB1 is predominantly nuclear (UniProt Q9Y5A7). A mixed pattern alone cannot identify a failed step. | Examine the hematoxylin counterstain to locate nuclei, compare a reported positive population and review run controls (general IHC practice; HPA tissue IHC). Describe both compartments instead of forcing a binary positive call. |
| An IF/ICC image appears nucleolar while tissue IHC looks broader. | Enhanced nucleoplasm and nucleoli localisation is reported for ICC-IF (HPA subcellular); tissue IHC is described as nuclear and cytoplasmic with variable intensity (HPA tissue IHC). | Interpret each image against its own assay's reported pattern (HPA subcellular; HPA tissue IHC). Avoid using the IF localisation description as a requirement that every chromogenic tissue section resolve nucleoli. |
Experiment evidence
IHC & IF images showing NUB1 staining
A06089-2 · IHCIHC analysis of NUB1 using anti-NUB1 antibody (A06089-2). NUB1 was detected in a paraffin-embedded section of human adrenal adenomas tissue.
A06089-2 · IHCIHC analysis of NUB1 using anti-NUB1 antibody (A06089-2). NUB1 was detected in a paraffin-embedded section of human bladder urothelial carci
A06089-2 · IFIF analysis of NUB1 using anti-NUB1 antibody (A06089-2) and anti-Beta Tubulin antibody (M01857-3). NUB1 was detected in immunocytochemical s
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000013374-NUB1/tissue/cerebral+cortex#imid_15918108
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000013374-NUB1/tissue/colon#imid_15918050
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000013374-NUB1/tissue/liver#imid_15918051
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000013374-NUB1/tissue/kidney#imid_15918052
HPA · ICC-IF HEK293Human Protein Atlas immunofluorescence, HEK293, antibody HPA050722; green = NUB1, blue = nucleus, red = microtubules.
HPA · ICC-IF HEK293Human Protein Atlas immunofluorescence, HEK293, antibody HPA050722; green = NUB1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NUB1 IHC & IF
🧪Run lung first: macrophages should stain (HPA: High in lung macrophages). Use adipose tissue as the negative comparator, scoring adipocytes (HPA: Not detected in adipocytes); on the lung slide, assess neighboring non-macrophage cells for background staining without assuming they are NUB1-negative (HPA: lung row reports macrophages only).
Positive control tissue: Lung (Macrophages, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NUB1 in HEK293, MCF-7, U2OS, with annotated localisation: Nucleoplasm (enhanced), Nucleoli (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a rabbit IgG isotype control matched to the catalog antibody’s clonality (selected-SKU caption: rabbit anti-NUB1); use NUB1-knockout material as a biological negative where available (standard IHC practice). Check endogenous peroxidase activity in lung macrophages before interpreting DAB staining (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not state a fixative (selected-SKU caption: fixative not stated). The caption reports heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required (selected-SKU caption: EDTA retrieval); the supplied evidence does not establish whether frozen sections or IF/ICC are easier. Lung macrophage peroxidase activity can complicate chromogenic scoring (standard IHC practice); IF/ICC has a separate guide (application scope).
HPA tissue IHC evidence for NUB1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Lung | Macrophages | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Colon | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Basal cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cerebral cortex | Endothelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced NUB1 IHC Tips
Troubleshoot NUB1 staining in paraffin sections by checking retrieval, compartment, cell type and controls before comparing staining intensity across samples.
Which retrieval conditions should I start with for NUB1 paraffin sections?
Start with heat-mediated retrieval in EDTA at pH 8.0 for the catalog antibody (datasheet A06089-2). Its paraffin-section example then uses 2 μg/ml primary antibody overnight at 4°C, so keep those conditions fixed while assessing retrieval (caption A06089-2). If staining is weak, compare adjacent sections after a modest change in heating duration, recording tissue damage and nuclear detail; this is a controlled optimization, not an established NUB1 requirement (standard IHC practice). Include a no-primary control with each retrieval condition to distinguish improved signal from increased background (standard IHC practice). Score glandular cells in the adrenal section consistently across conditions, since expression intensity varies by cell type (HPA: adrenal glandular cells Medium; HPA: variable intensity).
Could fixation explain weak or uneven NUB1 staining?
NUB1-specific fixation sensitivity is unknown from the supplied evidence, and the catalog paraffin-section caption does not state a fixative (caption A06089-2). Record the actual fixative and fixation duration for each specimen, then compare sections processed together before changing antibody concentration (standard IHC practice). Uneven staining can reflect differences in fixation, section handling or detection, so assess morphology and a no-primary control alongside NUB1 (standard IHC practice). Keep retrieval at EDTA pH 8.0 during that comparison because it is the documented condition for this antibody (datasheet A06089-2). Do not assign a NUB1-specific fixation effect from its predominantly nuclear location or lack of a transmembrane segment (UniProt Q9Y5A7: subcellular location and topology).
How should I assess nuclear and cytoplasmic NUB1 staining?
Expect predominantly nuclear NUB1 by UniProt annotation, while tissue IHC reports nuclear and cytoplasmic expression with variable intensity (UniProt Q9Y5A7: subcellular location; HPA: tissue IHC profile). Judge nuclear and cytoplasmic DAB separately against the counterstain, and record the fraction of positive cells in each compartment (standard IHC practice). HPA places NUB1 mainly in nucleoplasm and nucleoli in its subcellular assessment, which can guide inspection but does not establish the catalog antibody’s tissue staining pattern (HPA: subcellular summary; caption A06089-2). A predominantly membranous rim would conflict with the annotated lack of a transmembrane segment and warrants control review (UniProt Q9Y5A7: topology; standard IHC practice).
Can this stain distinguish NUB1 isoforms or epitope masking?
NUB1 has 2 annotated isoforms, but the supplied catalog caption gives no epitope position or evidence of isoform discrimination (UniProt Q9Y5A7: isoforms; caption A06089-2). Therefore, report staining as NUB1 immunoreactivity rather than assigning it to isoform 1 or 2 (UniProt Q9Y5A7: isoforms; standard IHC interpretation). The 3 annotated UBA domains lie at residues 374–413, 424–470 and 489–529; their positions alone cannot identify the antibody’s epitope (UniProt Q9Y5A7: domains). If staining changes after retrieval, check preserved morphology and background before calling it epitope unmasking (standard IHC practice). An isoform-specific conclusion requires an antibody epitope or independent validation that distinguishes the isoforms (standard IHC practice).
How should I adapt NUB1 assessment for multiplex immunofluorescence?
Treat multiplex IF as a separate assay requiring validation of the chosen antibody and detection conditions; the catalog evidence here documents paraffin-section chromogenic IHC (caption A06089-2). Pair NUB1 with a validated marker for the expected cell type, such as a macrophage marker when examining lung, and inspect nuclear overlap with a DNA counterstain (HPA: lung macrophages High; standard IF practice). Choose spectrally separated fluorophores after checking tissue autofluorescence, using single-stain and no-primary controls to assess bleed-through and background (standard IF practice). NUB1 lacks a transmembrane segment and is predominantly nuclear, so optimize permeabilisation for access to intracellular and nuclear epitopes while checking cell morphology (UniProt Q9Y5A7: topology and subcellular location; standard IF practice).
What should I check when NUB1 DAB staining is diffuse?
Run a no-primary control and inspect whether diffuse DAB persists; persistent colour implicates the detection workflow or tissue rather than primary-antibody binding (standard IHC practice). Include an endogenous peroxidase block before HRP detection and control DAB development consistently across sections (standard chromogenic IHC practice). The catalog example uses 10% goat serum block, 2 μg/ml primary overnight at 4°C, and a peroxidase-conjugated secondary for 30 minutes at 37°C (caption A06089-2). If background rises with primary antibody, compare a lower concentration and stronger washing on matched sections while retaining EDTA pH 8.0 retrieval (standard IHC practice; datasheet A06089-2). Assess nuclear detail before interpreting diffuse cytoplasmic colour, because HPA reports variable nuclear and cytoplasmic staining (HPA: tissue IHC profile).
How should I quantify NUB1 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue region and cell population before scoring, because NUB1 intensity varies among cell types in tissue IHC (HPA: tissue IHC profile). For a defined population, report nuclear and cytoplasmic H-scores separately, or report the percentage of positive cells with a prespecified intensity threshold (standard IHC scoring practice). If counting discrete positive cells, express density per mm² of viable tissue and exclude empty spaces and necrosis consistently (standard IHC quantification practice). Normalize comparisons to the number of eligible cells or viable tissue area, and hold staining batch, counterstain and image-analysis thresholds constant (standard IHC practice). Record which compartment and cell type each score represents so a shift in tissue composition is not mistaken for a change in NUB1 expression (HPA: variable cell-type intensity; standard IHC interpretation).
How can I distinguish true NUB1 signal from staining artefacts?
A credible result has interpretable cellular staining and agrees with an expected compartment or documented cell pattern: NUB1 is predominantly nuclear, while HPA tissue IHC also reports cytoplasmic signal (UniProt Q9Y5A7: subcellular location; HPA: tissue IHC profile). Lung macrophages are reported High and adrenal glandular cells Medium, so identify the stained cell type before comparing fields (HPA: positive tissue IHC). Treat staining confined to section edges, necrotic areas or a no-primary control as suspect, and check endogenous peroxidase blocking when using HRP/DAB (standard chromogenic IHC practice). Uniform membranous staining is difficult to reconcile with NUB1’s lack of a transmembrane segment and should prompt a control review (UniProt Q9Y5A7: topology; standard IHC interpretation). HPA rates tissue staining Approved with medium RNA agreement, so corroborate unexpected patterns independently (HPA: reliability description; standard IHC practice).
Boster reagents
Best NUB1 / NEDD8 ultimate buster 1 IHC Antibodies
A06089-2 has IHC images from human paraffin sections and an IF image from HeLa cells (IHC and IF captions). Listed reactivity covers human, monkey, mouse and rat (catalog reactivity).
Real IHC data
Anti-NUB1 Antibody ®
Cat # A06089-2
A06089-2 is listed for IHC and IF/ICC, with IHC images from human adrenal adenomas, bladder urothelial carcinoma and ovarian cancer paraffin sections (catalog applications; IHC captions). Its IF image shows HeLa cells, and its listed reactivity is human, monkey, mouse and rat (IF caption; catalog reactivity).
Which to pick: For tissue IHC, choose A06089-2: its own captions document human paraffin sections, EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody; the fixative is unreported (IHC captions). For IF/ICC, the same SKU has a HeLa cell IF image using 5 μg/ml primary antibody (IF caption). For monkey, mouse or rat samples, A06089-2 lists reactivity with those species, while the supplied IHC and IF images show human samples (catalog reactivity; IHC and IF captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9Y5A7 (NUB1_HUMAN, NEDD8 ultimate buster 1).
- Human Protein Atlas. NUB1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. NUB1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm and nucleoli..
- Human Protein Atlas. NUB1 antibody validation summary (3 antibodies).
- Altered fibroblast-like synoviocyte epigenetics is responsible for deficient NUB1 expression in rheumatoid arthritis. Scientific reports 2026 — PMC12960655.
- Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant α-synuclein in presynapses in Lewy body disease. Journal of neuropathology and experimental neurology 2011 — PMC3181070.
- Mechanism and Predictive Role of NUB1 Protein in Oestrogen Receptor Pathway of FEC-Treated Breast Cancer Patients. Biomedicines 2025 — PMC12189139.
- NUB1 reduction promotes PCNA-mediated tumor growth by disturbing the PCNA polyubiquitination/NEDDylation in hepatocellular carcinoma cells. Cell death & disease 2025 — PMC11958677.
- PubMed PMID:10508479 — UniProt-cited evidence.
- PubMed PMID:11259415 — UniProt-cited evidence.
- PubMed PMID:12816948 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NUB1 (NEDD8 ultimate buster 1). Expected localisation Nuclear and cytoplasmic staining varies by cell type (HPA tissue IHC).. Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A06089-2). Validated IHC antibody: A06089-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Lung (Macrophages); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human adrenal adenomas tissue; fixative not specified (datasheet A06089-2); 2. Fixation: Image fixative and duration unreported (datasheet A06089-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A06089-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06089-2); 8. Primary antibody: Rabbit anti-NUB1, 2-5 μg/ml (datasheet A06089-2); 9. Primary incubation: Overnight at 4 °C (datasheet A06089-2). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06089-2); Caveat: Macrophage-rich areas may dominate staining (HPA tissue IHC).; Isoform / epitope: 2 isoforms; verify epitope coverage for each (UniProt).; Regulation: Intensity varies by cell type (HPA tissue IHC).. Evidence: UniProt Q9Y5A7, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm and nucleoli., Datasheet A06089-2, PMC12960655, PMC3181070. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NUB1/immunohistochemistry-ihc-guide.